Impact News +++ Investor Alert: Berger Montague (Canada) PC Investigates Potential Claims on Behalf of Canadian Investors in... (PR Newswire) +++ HUT 8 Aktie -3,20%

CARDIOL Aktie

>CARDIOL Aktienkurs

0.95 EUR +4.5% (Tradegate)

Ask: 0.951 EUR / 1100 Stück

Bid: 0.925 EUR / 1100 Stück

Tagesumsatz: 1632 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CARDIOL Aktie über LYNX handeln

Intraday

1 Jahr

>CARDIOL Performance

1 Woche: +3,1%

1 Monat: -9,5%

3 Monate: -17,4%

6 Monate: -7,8%

1 Jahr: -52,9%

laufendes Jahr: -23,0%

>CARDIOL Aktie

Name:

CARDIOL THERAPEUTICS CL.A

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA14161Y2006 / A2PA9E

Symbol/ Ticker:

CT9 (Frankfurt)

Kürzel:

FRA:CT9, ETR:CT9, CT9:GR

Index:

Webseite:

https://www.cardiolrx.com..

Profil:

Cardiol Therapeutics Inc. is a clinical-stage biot..
>Volltext..

Marktkapitalisierung:

75.55 Mio. EUR

Unternehmenswert:

64.28 Mio. EUR

Umsatz:

EBITDA:

-24.75 Mio. EUR

Nettogewinn:

-23.27 Mio. EUR

Gewinn je Aktie:

-0.3 EUR

Schulden:

0.09 Mio. EUR

Liquide Mittel:

11.28 Mio. EUR

Operativer Cashflow:

-15.54 Mio. EUR

Bargeldquote:

2.27

Umsatzwachstum:

Gewinnwachstum:

-16.98%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CARDIOL

Letzte Datenerhebung:

18.09.25

>CARDIOL Kennzahlen

Aktien/ Unternehmen:

Aktien: 83.73 Mio. St.

Frei handelbar: 95.22%

Leerverk. Aktien: -

Rückkaufquote: -15.37%

Mitarbeiter: 22

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 705.41%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 10.32

PEG-Ratio: -0.32

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -162.37%

Eigenkaprendite: -276.41%

>CARDIOL Peer Group

Es sind 186 Aktien bekannt.

>CARDIOL Chart & Kurs - Tradegate

>CARDIOL News

11.08.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity′s 45th Annual Growth Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developi......

06.08.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis (Newsfile)
	Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with i......

22.07.25 - 21:03	Cardiol rises on database lockup for acute myocarditis therapy trial (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.07.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx in Acute Myocarditis (Newsfile)
	ARCHER is designed to assess the impact of CardiolRx on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis i......

29.05.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......

27.05.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing ......

29.04.25 - 13:48	Cardiol Therapeutics Inc.: Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developin......

22.04.25 - 15:15	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
	Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors....

16.04.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis (Newsfile)
	Designed to assess the impact of CardiolRx on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-o......

01.04.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Year-End 2024 Update on Operations (Newsfile)
	Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis; results support advancing to th......

03.03.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing......

20.02.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, f (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on develo......

04.02.25 - 16:12	Cardiol Therapeutics to present at Oppenheimer Healthcare Conference (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

04.02.25 - 13:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the res......

03.02.25 - 11:30	Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol (Zacks)
	Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article....

18.11.24 - 20:26	Cardiol Therapeutics präsentiert klinische Ergebnisse der Phase-II-Pilotstudie MAvERIC zu rezidivierender Perikarditis bei den Scientific Sessions 2024 der American Heart Association (IRW Press)
	- Eine deutliche und rasche Reduktion sowohl der Perikarditis-bedingten Schmerzen als auch der Entzündungen wurde während der 26-wöchigen Studie aufrechterhalten- Anzahl der......

18.11.24 - 17:43	Cardiol Therapeutics Inc.: Cardiol Therapeutics′ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 (Newsfile)
	Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support ......

22.10.24 - 16:50	Cardiol Therapeutics will CardiolRx™ in eine Studie der späten Phase an Patienten mit rezidivierender Perikarditis überführen (IRW Press)
	Die Studie MAVERIC-2 wird die Auswirkungen von CardiolRx'¢ nach dem Absetzen einer Therapie mit Interleukin-1-Blockern (Rilonacept oder Anakinra) beurteilen und wird voraussichtlich zeitgleich......

22.10.24 - 12:42	Cardiol Therapeutics Inc.: Cardiol Therapeutics to Advance CardiolRx into a Late-Stage Trial in Patients with Recurrent Pericarditis (Newsfile)
	Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the res......

11.10.24 - 14:55	Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option (Newsfile)
	Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the re......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Arbeit ist die zuverlässigste Seligkeit dieser Erde. - Ernst Wiechert

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram